Laekna Inc., a company incorporated in the Cayman Islands, has announced that it has obtained Investigational New Drug $(IND.AU)$ approval from the U.S. Food and Drug Administration (FDA) for its internally discovered monoclonal antibody, LAE103. This approval marks a significant step in advancing LAE103, an ActRIIB selective antibody, to clinical studies aimed at treating sarcopenic obesity and other muscle-related diseases. The company emphasizes that while this approval is a crucial milestone, there remains the risk that LAE103 may not ultimately be successfully developed and commercialized. The announcement serves to inform shareholders and potential investors of this important business update.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.